Skip to content

Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.

Powered by THEMA

Current Report · Items 5.02, 7.01, 9.01 · 8-K

Becton, Dickinson and Co.

BDXNYSEEQUITYCurrent

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure

Item 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. On July 19, 2026, Michael D. Garrison, Executive Vice President and President of the Medical Essentials and BioPharma Systems segments of Becton, Dickinson and Company (“BD”), informed BD of his intention to retire. Dr.…

Filed Jul 22, 2026Accepted Jul 22, 2026, 6:58 AM EDTCIK 10795Accession 0001628280-26-049103

View company →Permanent SEC source ↗

Press release in this filing

Mike Garrison to Retire from BD →

Company context

Current securities

BDXNYSE · EQUITY · Current

Historical securities (2)

BDXBNYSE · PREFERRED · Historical · closed May 31, 2023 BKDCLOTC · PREFERRED · Historical · closed Jun 3, 2020

Recent company filings

Registered securities in this filing

BECTON, DICKINSON AND COMPANY · 8-K · Filed 2026-07-22

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common stock, par value $1.00

Symbol: BDX
Exchange: NYSE
Classification: COMMON
Status: Current

Filing context

Context: c-2

Dimensions: us-gaap:StatementClassOfStockAxis

1.900% Notes due December 15, 2026

Symbol: BDX26
Exchange: NYSE
Classification: DEBT

Filing context

Context: c-3

Dimensions: us-gaap:StatementClassOfStockAxis

1.213% Notes due February 12, 2036

Symbol: BDX/36
Exchange: NYSE
Classification: DEBT

Filing context

Context: c-4

Dimensions: us-gaap:StatementClassOfStockAxis

3.519% Notes due February 8, 2031

Symbol: BDX31
Exchange: NYSE
Classification: DEBT

Filing context

Context: c-5

Dimensions: us-gaap:StatementClassOfStockAxis

3.828% Notes due June 7, 2032

Symbol: BDX32A
Exchange: NYSE
Classification: DEBT

Filing context

Context: c-6

Dimensions: us-gaap:StatementClassOfStockAxis

3.855% Notes due May 20, 2033

Symbol: BDX33A
Exchange: NYSE
Classification: DEBT

Filing context

Context: c-7

Dimensions: us-gaap:StatementClassOfStockAxis

Accession 000162828026049103 · 6 registered-security cover members

Read the exact SEC filing ↗

Disclosure sections

Items 5.02, 7.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.02Item 5.02 - Departure/Election of Directors

Item 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. On July 19, 2026, Michael D. Garrison, Executive Vice President and President of the Medical Essentials and BioPharma Systems segments of Becton, Dickinson and Company (“BD”), informed BD of his intention to retire. Dr. Garrison will remain in his role through the end of the fiscal year to support a smooth transition. A comprehensive search is underway to identify the next President of the Medical Essentials segment. Going forward, to streamline BD's operating model, the BioPharma Systems segment will report directly to Thomas E. Polen, Chairman, CEO and President of BD.

Item 7.01Item 7.01 - Regulation FD Disclosure

Item 7.01 REGULATION FD DISCLOSURE On July 22, 2026, BD issued a press release relating to the matters described above in Item 5.02. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 7.01 by reference. The information in this Item 7.01 shall neither be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.